The safety of chitosan as a pharmaceutical excipient.

Baldrick Paul
Regulatory toxicology and pharmacology, 2010

Abstract

Interest in use of the polysaccharide chitosan as a pharmaceutical excipient by different dose routes and for a number of applications is not new but it still does not appear to be present in any marketed drugs. Including a novel excipient in a new drug formulation requires a number of safety considerations. Review of the published literature showed that chitosan has low oral toxicity and local tolerance potential supporting use in non-parenteral formulations. Prior human oral exposure has occurred through use of chitosan dietary supplements and food additive, medical device and cosmetic applications. Although systemic exposure to parent chitosan may be limited (due to digestion in the gastrointestinal tract), any that is absorbed will likely undergo enzyme degradation to naturally occurring glucosamine, and N-acetylglucosamine, its copolymers, which are excreted or used in the amino sugar pool. Chitosan has local biological activity in the form of haemostatic action and, together with its ability to activate macrophages and cause cytokine stimulation (which has resulted in interest in medical device and wound healing applications), may result in a more careful assessment of its safety as a parenteral excipient.

Copyright 2009 Elsevier Inc. All rights reserved.

Articles similar to "The safety of chitosan as a pharmaceutical excipient."

• The properties of Chitosan: Chitosan as a starting material for wound healing applications. (Chitosan and its derivatives have attracted great attention due to their properties beneficial for application to wound healing...)
• The properties of Chitosan: Quantitative assessment of the effects of chitosan intervention on blood pressure control. ( Chitosan is a popular dietary fiber often used to reduce dietary fat absorption to control weight and blood lipids... This meta-analysis indicates that chitosan consumption significantly decreases DBP at higher dosage and in shorter-term interventions, while chitosan has no significant effects on SBP. However, these results should be interpreted cautiously because of the limited eligible RCTs included in this meta-analysis; further large-scale, well-designed RCTs on this topic are urgently needed. )
• The properties of Chitosan: The potential of chitosan and its derivatives in prevention and treatment of age-related diseases. (Age-related, diet-related and protein conformational diseases, such as atherosclerosis, diabetes mellitus, cancer, hypercholesterolemia, cardiovascular and neurodegenerative diseases are common in the elderly population... This meta-analysis indicates that chitosan consumption significantly decreases DBP at higher dosage and in shorter-term interventions, while chitosan has no significant effects on SBP. However, these results should be interpreted cautiously because of the limited eligible RCTs included in this meta-analysis; further large-scale, well-designed RCTs on this topic are urgently needed. )
• The properties of Chitosan: Chitosan as potential marine nutraceutical. (Chitosan, the most abundant marine mucopolysaccharide, is derived from chitin by alkaline deacetylation, and possesses versatile biological properties such as biocompatibility, biodegradability, and a non-toxic nature... This meta-analysis indicates that chitosan consumption significantly decreases DBP at higher dosage and in shorter-term interventions, while chitosan has no significant effects on SBP. However, these results should be interpreted cautiously because of the limited eligible RCTs included in this meta-analysis; further large-scale, well-designed RCTs on this topic are urgently needed. )
• The properties of Chitosan: Recent patents on food applications of chitosan. (Chitosan is a natural polysaccharide that has become of great interest due to its multiple possible applications, which is a great challenge for both the scientific community and the food industry... This meta-analysis indicates that chitosan consumption significantly decreases DBP at higher dosage and in shorter-term interventions, while chitosan has no significant effects on SBP. However, these results should be interpreted cautiously because of the limited eligible RCTs included in this meta-analysis; further large-scale, well-designed RCTs on this topic are urgently needed. )

Previous article

Recent patents on food applications of chitosan.

Next article

Elemental analysis and nutritional value of edible Trifolium (clover) species.